Peptide Surf a research-only wiki of supplements & peptides
Research & educational use only. This site catalogs published research and public commentary about supplements and peptides. It is not medical advice and not a recommendation to use any compound. Consult a qualified clinician.
← Catalog

Tirzepatide

peptide Metabolic & Weight Management

A dual agonist that activates both the GLP-1 and GIP receptors (GIP is a second incretin peptide released after meals). Described as a more powerful successor to semaglutide for appetite and weight reduction. FDA-approved (Mounjaro / Zepbound) and studied in tens of thousands of people.

Synonyms

Mounjaro · brand Zepbound · brand GLP-1/GIP dual agonist · other twincretin · other

Synonyms drive on-site search and are used to index ingested research papers and tweets to this page.

Safety

Contraindications

  • Personal/family history of medullary thyroid carcinoma or MEN 2
  • History of pancreatitis (discuss with a clinician)

Reported side effects

  • Nausea, vomiting, GI disturbance
  • Reduced appetite

FDA-approved and extensively trialed. This page summarizes public information and commentary and is not medical advice.

Protocols

No structured protocols recorded.

Claims & evidence

Produces weight loss via combined GLP-1 and GIP receptor agonism, with effect sizes generally exceeding semaglutide.

Weight loss positive meta-analysis

Notes

Overview

Tirzepatide extends the GLP-1 mechanism by adding GIP receptor activity, which the source article frames — together with semaglutide — as the best-evidenced and safest starting point in the peptide category.